Stockscreener 앱 받기
0.00
9,900%
0.0005
Vaxxinity Inc 주식(VAXX)의 최신 뉴스
Head to Head Contrast: ANI Pharmaceuticals (NASDAQ:ANIP) vs. Vaxxinity (NASDAQ:VAXX) - Defense World
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - MSN
Comparing Dynavax Technologies (NASDAQ:DVAX) & Vaxxinity (NASDAQ:VAXX) - Defense World
How a new kind of vaccine could lead to the eradication of Alzheimer's and dementia - New Scientist
Vaxxinity - The Pharma Letter
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial - Nature
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace
Vaxxinity Issues Shareholder Letter - GlobeNewswire
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewswire
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
Vaxxinity Announces Positive Target Engagement Data from - GlobeNewswire
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - GlobeNewswire
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - GlobeNewswire
Vaxxinity, University of Florida join for work on Parkinson’s vaccine - Parkinson's News Today
Vaxxinity, UF Join Forces Against Neurodegenerative Diseases - Yahoo Finance
Could space travel research deliver a frailty vaccine? - Longevity.Technology
Vaxxinity, University of Central Florida launch collaboration to advance medicines for use in space - Fierce Biotech
Vaxxinity making vaccines to change the world - Labiotech.eu
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Mei Mei Hu - The World Economic Forum
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline - Yahoo Finance
Baird Starts Vaxxinity With Outperform Rating, Price Target is $7 - MarketScreener
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX) - Yahoo Finance
Fast-Tracked Alzheimer’s Vaccine Seems to Work, But Phase 3 Trials Stalled - Being Patient
Vaxxinity Alzheimer’s treatment shows promising results in early trial - BioPharma-Reporter.com
Innovative Alzheimer's Disease Vaccine Candidate Can Add Value - Vax-Before-Travel
Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director - Yahoo Finance
Vaxxinity Appoints Peter Powchik, M.D., to EVP, Global Scientific Director - citybiz
Promising Milestone in Neurodegenerative Disease Treatment: Vaxxinity’s UB-312 in Parkinson’s Patients - Yahoo 財經
Michael J. Fox Foundation Funds Parkinson’s Disease Vaccine Candidate - Vax-Before-Travel
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease - southfloridahospitalnews.com
Vaxxinity celebrates trial success in early Parkinson’s therapy - Clinical Trials Arena
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease - GlobeNewswire
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recap - Investing.com India
VXX-301, a tau vaccine with optimized properties - BioWorld MedTech
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April - Yahoo News Canada
Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates - GlobeNewswire
Clinical Trial of Investigational Vaccine to Treat LDL Cholesterol Underway - Diagnostic and Interventional Cardiology
Vaxxinity Announces First Subjects Dosed in Phase 1 - GlobeNewswire
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences - GlobeNewswire
Vaxxinity Announces Board Appointments - citybiz
Why Shares of Vaxxinity Jumped This Week - The Motley Fool
Vaxxinity Stock: Potential Strong Upsides Ahead (NASDAQ:VAXX) - Seeking Alpha
Robinhood Gave Its Customers Access to IPOs That All Flopped - Bloomberg
Multiple insiders bought Vaxxinity, Inc. (NASDAQ:VAXX) stock earlier this year, a positive sign for shareholders - Yahoo Finance
Vaxxinity vaccine to treat Alzheimer’s wins FDA fast-track designation - Dallas News
Insiders who bought stock earlier this year lose -US$216k as Vaxxinity, Inc. (NASDAQ:VAXX) drops to US$505m - Yahoo Finance
CEPI to co-fund Vaxxinity's Phase III UB-612 trial to combat SARS-CoV-2 variants - The Pharma Letter
Dallas-based Vaxxinity begins Phase 3 trial for COVID-19 booster vaccine - Dallas News
CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants - CEPI
Vaxxinity looks to pioneer the next revolution in pharma - PharmaVoice
Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study - Yahoo Finance
Vaccitech, Vaxxinity stock prices hit post-IPO lows as Omicron rally fades (Nasdaq:VAXX) - Seeking Alpha
Vaxxinity Has a Rough Public Debut - The Motley Fool
Vaxxinity (VAXX) Stock Price, News & Analysis - MarketBeat
Vaxxinity raises $85 million with its push into the public markets - The Business Journals
Biotech Companies Launch or Plan IPOs: Vaxxinity, Genenta and Enetrada - BioSpace
Dallas-Based Vaxxinity Prepares for $100M IPO; Aims to Turn Immune Systems Into 'Antibody Factories' - Dallas Innovates
VAXX IPO NewsVaccine biotech Vaxxinity sets terms for $101 million IPO - Renaissance Capital
Vaxxinity (VAXX) IPO: Pioneering Vaccines For Chronic Diseases - Seeking Alpha
Vaxxinity CEO says the U.S. needs more vaccine options - Fortune
Vaxxinity Signs Purchase Order with the Government of Paraguay for 1 Million Doses of Vaxxinity’s UB-612 COVID-19 Vaccine - Business Wire
Vaxxinity hopes its Covid jab technology will help treat Alzheimer’s - Financial Times
EXCLUSIVE Blackwater founder Prince takes role in COVID vaccine venture - Reuters
Aurobindo and Vaxxinity seek DCGI approval for Covid-19 vaccine trial - Clinical Trials Arena
Vaxxinity CEO Mei Mei Hu on vaccine research and democratising health - Clinical Trials Arena
How We Have Changed For The Better Thanks To COVID-19 - Life Science Leader Magazine
COVAXX and United Neuroscience Are Now Vaxxinity - Business Wire
17.27%
1.06%
자본화:
|
볼륨(24시간):